Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized and Controlled Phase IIb Study to Evaluate the Efficacy and Safety of D-0120 Tablets in Patients with Primary Hyperuricemia

NCT05504083 is registered in ClinicalTrials.gov with InventisBio Co., Ltd as lead sponsor.

NCT NCT05504083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05504083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized and Controlled Phase IIb Study to Evaluate the Efficacy and Safety of D-0120 Tablets in Patients with Primary Hyperuricemia
Lead sponsor
InventisBio Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
September 28, 2022
Completion date
May 18, 2024
Enrollment
121 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

hyperuricemia